Investment analysts at Oppenheimer Holdings, Inc. initiated coverage on shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) in a research report issued to clients and investors on Thursday. The brokerage set an “outperform” rating and a $19.00 price target on the biotechnology company’s stock. Oppenheimer Holdings, Inc.’s target price would indicate a potential upside of 74.79% from the company’s previous close.

Several other research firms have also weighed in on MCRB. BidaskClub lowered shares of Seres Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, August 11th. ValuEngine upgraded shares of Seres Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, August 1st. Zacks Investment Research lowered shares of Seres Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, August 8th. Cantor Fitzgerald reiterated a “buy” rating on shares of Seres Therapeutics in a research note on Wednesday, August 30th. Finally, Seaport Global Securities reiterated a “buy” rating and set a $20.00 price objective on shares of Seres Therapeutics in a research note on Friday, October 6th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $17.88.

Seres Therapeutics (NASDAQ MCRB) opened at 10.87 on Thursday. The company has a 50-day moving average price of $14.20 and a 200 day moving average price of $14.20. Seres Therapeutics has a 12 month low of $8.85 and a 12 month high of $17.42. The firm’s market cap is $440.37 million.

Seres Therapeutics (NASDAQ:MCRB) last released its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.10). The business had revenue of $3.00 million for the quarter, compared to analyst estimates of $3.00 million. Seres Therapeutics had a negative return on equity of 80.21% and a negative net margin of 441.38%. Seres Therapeutics’s revenue was up .0% compared to the same quarter last year. During the same quarter last year, the company earned ($0.70) EPS. Equities research analysts anticipate that Seres Therapeutics will post ($2.55) EPS for the current year.

COPYRIGHT VIOLATION WARNING: This article was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/10/12/seres-therapeutics-inc-mcrb-coverage-initiated-by-analysts-at-oppenheimer-holdings-inc.html.

Several large investors have recently made changes to their positions in the business. Vanguard Group Inc. increased its stake in shares of Seres Therapeutics by 1.2% in the second quarter. Vanguard Group Inc. now owns 1,585,026 shares of the biotechnology company’s stock valued at $17,911,000 after purchasing an additional 19,363 shares during the period. ARK Investment Management LLC increased its stake in shares of Seres Therapeutics by 21.5% in the second quarter. ARK Investment Management LLC now owns 765,191 shares of the biotechnology company’s stock valued at $8,647,000 after purchasing an additional 135,276 shares during the period. JPMorgan Chase & Co. increased its stake in shares of Seres Therapeutics by 15.9% in the first quarter. JPMorgan Chase & Co. now owns 370,225 shares of the biotechnology company’s stock valued at $4,172,000 after purchasing an additional 50,860 shares during the period. State Street Corp increased its stake in shares of Seres Therapeutics by 12.0% in the second quarter. State Street Corp now owns 321,699 shares of the biotechnology company’s stock valued at $3,637,000 after purchasing an additional 34,393 shares during the period. Finally, Northern Trust Corp increased its stake in shares of Seres Therapeutics by 16.2% in the second quarter. Northern Trust Corp now owns 235,766 shares of the biotechnology company’s stock valued at $2,664,000 after purchasing an additional 32,875 shares during the period. Institutional investors own 74.76% of the company’s stock.

About Seres Therapeutics

Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.

Analyst Recommendations for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.